Editas Medicine (EDIT) Capital Expenditures Growth (1y) (2016 - 2025)
Powered by 
Analysis
Editas Medicine (EDIT) Capital Expenditures Growth (1y) (2016 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -100.03% |
| Mar 31, 2025 | -154.78% |
| Dec 31, 2024 | -58.68% |
| Sep 30, 2024 | 1,122.18% |
| Jun 30, 2024 | 162.12% |
| Mar 31, 2024 | 1.68% |
| Dec 31, 2023 | 109.46% |
| Sep 30, 2023 | -61.07% |
| Jun 30, 2023 | 110.92% |
| Mar 31, 2023 | -18.15% |
| Dec 31, 2022 | -78.07% |
| Sep 30, 2022 | -73.81% |
| Jun 30, 2022 | -21.30% |
| Mar 31, 2022 | 13.25% |
| Dec 31, 2021 | 106.76% |
| Sep 30, 2021 | 30.73% |
| Jun 30, 2021 | -56.38% |
| Mar 31, 2021 | -7.76% |
| Dec 31, 2020 | -18.63% |
| Sep 30, 2020 | -20.13% |